The top pathways predicted to be positively affected by TGFβ treatment included idiopathic pulmonary fibrosis signaling and hepatic fibrosis/stellate cell activation, as well as the osteoarthritis pathway and axonal guidance signaling. The gene discussed is TGFB1; the disease is idiopathic pulmonary fibrosis.